Media Contacts
photo:Tulchan  Communications
Tulchan Communications
Tom Buchanan
020 7353 4200
Share this release
Share on: Twitter
Share on: Facebook
Share on: LinkedIn
Latest news
York,
10
September
2014

Tissue Regenix's dCELL® heart valve technology to be presented at prestigious Royal Society event

Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix" or "the Group"), the regenerative medical devices company, announces that its long-term clinical collaborator, Professor Francisco da Costa, has been asked to present the findings from his study into the Group's dCELL® heart valve at the 6th Biennial Heart Valve and Tissue Engineering Meeting at the Royal Society in London, on 12th September 2014.

The study findings suggest that fresh decellularised human heart valves, developed using Tissue Regenix's patented dCELL® technology, could provide a more effective treatment than cryopreserved decellularised pulmonary valve substitutes.

Professor Francisco da Costa is an internationally renowned cardiac surgeon from Pontifical University of Parana, Brazil, and the data in the report has been accumulated from more than 160 patient implants undertaken during Ross Procedures at his institution between 2005 and 2013 with follow-up review and patient monitoring up to the present date. 

Key findings of the study include that the fresh dCELL® heart valve has shown:

·     No reoperation up to now in a relatively young patient population (mean age 30 years)

·     No peak gradient above 40mmHg for up to six years

·     Significantly higher freedom from valve dysfunction (97% vs 85%)

·     No calcification

·     Partial re-population of the grafts

·     Particularly good results in younger patients

·     First indication that commonly used standard cryopreservation is unnecessary

Tissue Regenix's dCELL® technology decellularises human donor heart valves, producing an inert scaffold which is implanted into the patient to act as a mechanical scaffold that is populated by the patient's own cells. The dCELL® heart valve regenerates to become part of the patient's body, providing a more durable repair with proven significantly reduced risk of rejection and infection.

 

Antony Odell, CEO of Tissue Regenix
We are excited to see continued recognition for the effectiveness of the dCELL® heart valve technology, especially at this prestigious Royal Society Biennial Heart Valve and Tissue Engineering Meeting in London.

Professor da Costa has collaborated with Tissue Regenix for more than eight years to develop new, regenerative medicine treatments for patients with heart disease, and the data based on his studies show strong results and great promise for the dCELL® heart valve technology, targeted at the global tissue heart valve market which is worth in excess of $1.0bn a year.

This latest announcement comes on the back of further, recent positive updates on the development and commercialisation of our dCELL® treatments. This includes the DermaPure™ decellularised dermal allograft, where the US commercialisation continues at pace with initial orders having been received, and shipped to customers and continued progress being made in securing approvals by hospital new product evaluation committees - a key element in the inpatient sales process.
Antony Odell, CEO of Tissue Regenix